A majority of prostate cancer patients are still receiving primarily or exclusively androgen-receptor (AR)-directed therapies such as androgen deprivation therapy (ADT) or novel antiandrogens including enzalutamide and abiraterone [4]. The gene discussed is AR; the disease is prostate carcinoma.